The evidence question
Does the research show a benefit?
Ask what improved for patients, and how sure the result was.
Here, FDA refers to the Food and Drug Administration, the US agency for drugs.
In a 2024 assessment, FDA found that the research did not establish a benefit for any use it examined.
What does the research show?
In 2024, the FDA examined claims about infections, cancer and other illnesses. It also examined whether the peptide helps the body build defences after a vaccine.
It found that small studies and flaws in study design left the results unclear.
This does not prove that the peptide can never help; it means benefit had not been established for those uses.
What happened in the largest sepsis trial?
Sepsis is a life-threatening response to an infection.
The TESTS trial, published in 2025, assigned 1,106 hospital patients in China to the drug or a dummy shot.
Deaths over 28 days were 23.4% in the drug group and 24.1% in the comparison group.
The trial found no clear evidence that the drug reduced deaths.
SciClone Pharmaceuticals, the medicine’s maker, helped fund the trial.
These results concern people in hospital, rather than healthy adults hoping to strengthen their defences against illness.
Why do some reports sound more hopeful?
A 2025 review combined 11 sepsis trials. Its overall result suggested fewer deaths with the drug.
When the review kept only better-run trials, a benefit was no longer clear.
A US trial for hepatitis B, a liver infection, was published in 1999 and found no clear benefit among its 97 patients.
Ask whether the study is about your condition. Then ask whether it measured a change that matters to you, rather than a lab result alone.